Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Microbix Biosystems Inc.

Healthcare CA MBX

0.26CAD
0.03(13.04%)

Last update at 2026-03-10T16:12:00Z

Day Range

0.240.26
LowHigh

52 Week Range

0.210.55
LowHigh

Fundamentals

  • Previous Close 0.23
  • Market Cap33.36M
  • Volume110950
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.13962M
  • Revenue TTM18.59M
  • Revenue Per Share TTM0.13
  • Gross Profit TTM 9.85M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -2.30154M 3.67M -0.03948M 1.87M 3.23M
Minority interest - - - - -
Net income -2.24581M 3.52M -0.03948M 1.79M 1.63M
Selling general administrative 9.10M 8.63M 6.53M 5.00M 4.22M
Selling and marketing expenses - 0.25M 1.48M 1.55M 0.86M
Gross profit 9.85M 15.39M 7.48M 11.12M 11.04M
Reconciled depreciation 1.78M 1.61M 1.16M 1.04M 0.82M
Ebit -1.35113M 4.59M 0.80M 2.69M 4.84M
Ebitda 0.43M 6.21M 1.96M 3.73M 5.66M
Depreciation and amortization 1.78M 1.61M 1.16M 1.04M 0.82M
Non operating income net other - - - - -
Operating income -1.57615M 3.91M -2.73643M 2.69M 4.84M
Other operating expenses 20.16M 21.49M 19.25M 16.47M 13.76M
Interest expense 0.95M 0.92M 0.84M 0.83M 1.60M
Tax provision -0.05573M 0.15M 0.00000M 0.08M 0.00000M
Interest income 0.35M 0.69M 0.46M 0.08M -
Net interest income -0.59589M -0.23427M -0.38164M -0.74429M -1.60320M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.05573M 0.15M 0.84M 0.08M 1.60M
Total revenue 18.59M 25.39M 16.51M 19.08M 18.59M
Total operating expenses 11.43M 11.49M 10.22M 8.51M 6.21M
Cost of revenue 8.73M 10.00M 9.03M 7.95M 7.55M
Total other income expense net -0.72538M -0.23427M 2.70M -0.82656M -1.60320M
Discontinued operations - - - - -
Net income from continuing ops -2.24581M 3.52M -0.03948M 1.79M 3.23M
Net income applicable to common shares -2.24581M 3.52M -0.03948M 1.79M 3.23M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 37.41M 38.10M 35.65M 33.15M 28.83M
Intangible assets 3.73M 4.22M 4.42M 1.50M 1.65M
Earning assets - - - - -
Other current assets 0.66M 0.64M - 0.55M 0.50M
Total liab 9.62M 9.80M 11.03M 8.21M 10.27M
Total stockholder equity 27.79M 28.30M 24.62M 24.94M 18.56M
Deferred long term liab - - - - -
Other current liab - - - 1.83M 1.79M
Common stock 50.43M - - 49.92M 43.61M
Capital stock 50.43M 48.68M 49.04M 49.92M 43.61M
Retained earnings -35.63705M -33.39124M -36.91141M -36.87193M -38.66062M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.33M -
Cash 12.11M 12.96M 11.61M 13.49M 9.99M
Cash and equivalents - - - - -
Total current liabilities 2.78M 3.39M 4.35M 2.65M 5.19M
Current deferred revenue 0.59M - - 0.55M 0.74M
Net debt -5.33821M - - -7.66470M -2.25128M
Short term debt 0.22M - - 0.27M 2.66M
Short long term debt 0.00522M 0.11M 0.11M 0.11M 2.45M
Short long term debt total 6.77M - - 5.82M 7.74M
Other stockholder equity 10.72M - - 11.89M 13.61M
Property plant equipment 10.10M - - 8.91M 8.08M
Total current assets 23.57M 24.26M 22.30M 22.41M 19.09M
Long term investments - - - - -
Net tangible assets - - - 23.44M 16.90M
Short term investments - - - - -
Net receivables 1.61M 4.16M 4.12M 3.09M 4.21M
Long term debt 5.26M 5.59M 5.68M 4.71M 4.09M
Inventory 9.20M 6.46M 5.75M 5.28M 4.41M
Accounts payable 1.98M - - 1.83M 1.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.27M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.00000M - 0.33M -
Deferred long term asset charges - - - - -
Non current assets total 13.84M 13.84M 13.35M 10.74M 9.73M
Capital lease obligations 1.51M 0.70M 0.85M 1.00M 1.20M
Long term debt total 6.56M - - 5.56M 5.08M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -1.90675M -1.01623M -2.02564M -0.62234M
Change to liabilities - - - -0.52873M -0.53054M
Total cashflows from investing activities -0.79730M -1.90675M -1.01623M -2.02564M -0.62234M
Net borrowings -1.41798M -0.52249M 1.24M -1.38193M 0.08M
Total cash from financing activities 0.03M -1.08402M 0.23M 2.06M 8.41M
Change to operating activities - - - -0.05127M -0.27498M
Net income -2.24581M 3.52M -0.03948M 1.79M 3.23M
Change in cash -0.85058M 1.36M -1.88159M 3.50M 9.89M
Begin period cash flow 12.96M 11.61M 13.49M 9.99M 0.09M
End period cash flow 12.11M 12.96M 11.61M 13.49M 9.99M
Total cash from operating activities -0.08029M 4.35M -1.09456M 3.47M 2.11M
Issuance of capital stock - - - 0.00000M 6.13M
Depreciation 1.78M 1.61M 1.16M 1.04M 0.82M
Other cashflows from investing activities - -0.27060M - 0.00000M 0.68M
Dividends paid - - - - -
Change to inventory -2.73118M -0.71238M -0.46711M -0.87741M -0.11485M
Change to account receivables 2.58M -0.01271M -1.06197M 1.12M -2.29811M
Sale purchase of stock -1.73059M -0.92528M -1.11526M 3.44M 8.33M
Other cashflows from financing activities -0.21068M 0.36M 0.11M 4.52M 2.82M
Change to netincome - - - 0.98M 1.27M
Capital expenditures 0.80M 1.91M 1.02M 2.03M 1.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.75857M -1.77406M -0.21984M -0.34009M -3.21848M
Stock based compensation 0.65M 0.71M 0.74M 0.65M 0.38M
Other non cash items 1.14M 0.27M -2.72772M 0.33M 0.89M
Free cash flow -0.87758M 2.44M -2.11079M 1.44M 0.80M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MBX
Microbix Biosystems Inc.		 0.03 13.04% 0.26 - 17.24 1.79 1.12 1.39 60.47
EPRX
Eupraxia Pharmaceuticals Inc		 0.21 1.97% 10.86 - - - 7.79 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -0.48 4.64% 9.87 - 11.59 9.31 57.98 6.52 20.27
MSCL
Satellos Bioscience Inc.		 -2.98 18.90% 12.79 4.81 - - 5.61 6.47
HBP
Helix BioPharma Corp.		 0.10 5.41% 1.95 - - - 8.70 -6.3589

Reports Covered

Stock Research & News

View All

Profile

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Microbix Biosystems Inc.

265 Watline Avenue, Mississauga, ON, Canada, L4Z 1P3

Key Executives

Name Title Year Born
Mr. Cameron L. Groome Pres, CEO & Director NA
Mr. James S. Currie Chief Financial Officer NA
Dr. Kenneth Hughes Ph.D. Chief Operating Officer NA
Dr. Mark Luscher Ph.D. Sr. VP of Scientific Affairs NA
Mr. Philip Casselli Sr. VP of Sales, Bus. Devel. & Marketing NA
Mr. Christopher B. Lobb Compliance Officer, Gen. Counsel & Sec. NA
Mr. Cameron L. Groome President, CEO & Director NA
Dr. Mark Luscher Ph.D. Senior Vice President of Scientific Affairs NA
Mr. Philip Casselli Senior Vice President of Sales, Business Development & Marketing NA
Mr. Christopher B. Lobb Compliance Officer, General Counsel & Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.